TEM Tempus AI, Inc.
Trend channel, buy level and 3-month target. Information only, not financial advice.
Inside the channel · 9-month channel rising
Price is between the lines.
- 9-month channel read from
- US$65.17 – US$97.15 · rising, +61% a year
- 12-month channel
- US$64.96 – US$90.76 · falling, −13% a year
- Price in channel
- 22% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$90.76
- Turns bearish below
- US$65.17
- Published levels
- Buy and target are not from this channel — see below.
What broke this trend
- The fall
- -60% from US$103.178 Oct 2025 → 29 July 2026
- Whose problem it was
- This companyno peer group to compare against
- Does it resolve?
- Unsettled too close to a coin toss on the record to call
- Regained so far
- 50%of what it lost
- What the record says
- 55% of 556 comparable falls came back, typically in 139 days measured across every stock we hold history for, its peer group being too small
Fell -60% (8 Oct 2025 → 29 July 2026); regained 50% so far; company-specific.
Reported at the time: Nancy Pelosi's Tempus Play Might Be Smartest Trade In Washington — Stock Surges 200% — 8 Oct 2025
Price history, with the path projected 3 months forward
Updated 5:44 AM ET (30 h ago)
- Daily close
- Upper trend line (9 months)
- Lower trend line (9 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy at or below
US$72.22
level as at 1 Nov 2026
Our target
US$108.80
by 28 Jan 2027
Projected move
50.6%
gross, before costs
Price is at or below our buy.
Target: the projected upper line.
This move size: reached in 49% of 8 past stretches, typically in 90 days. (0.56% per day)
- Upper line touches
- 2
- Lower line touches
- 3
- Fit confidence
- 32%
- Fitted
- 1 Nov 2026
Company information
About Tempus AI, Inc.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky
- Employees
- 3,800
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$11.98B
- Enterprise value
- —
- Beta
- 3.54
- Avg volume
- 6.53M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 40.77-93.38
- Exchange
- NASDAQ
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.